6569.Two
6569.TWO is a company in the Advanced Medical Equipment & Technology industry, specializing in the development and provision of advanced medical equipment and technology solutions.
Business. 6569.TWO is a company in the Advanced Medical Equipment & Technology industry, specializing in the development and provision of advanced medical equipment and technology solutions.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
6569.TWO is a company in the Advanced Medical Equipment & Technology industry, specializing in the development and provision of advanced medical equipment and technology solutions.
6569.TWO has a market capitalization of 3.77 billion TWD and a price-to-earnings ratio of 33.62, indicating a relatively high valuation compared to its earnings. The company's price-to-book ratio is 2.4, suggesting that the market values the company at 2.4 times its book value. The company's liquidity is assessed as medium, with a current ratio of 2.17, indicating that it has sufficient current assets to cover its current liabilities.
In terms of profitability, 6569.TWO has a return on equity of 7.14% and a return on assets of 5.21%, which are metrics that reflect the company's efficiency in generating profits from its equity and assets. The company's operating income of 52.27 million TWD and net income of 112.13 million TWD indicate a positive earnings performance. The debt-to-equity ratio of 0.19 suggests that the company is not heavily leveraged and has a relatively low financial risk.
The company's revenue of 1.31 billion TWD is derived from its operations in the Advanced Medical Equipment & Technology industry. The revenue concentration is not specified, but the company's operations are primarily within the healthcare sector. The company's capital expenditure of -14.29 million TWD indicates that it is investing in its operations, which could be a sign of growth.
The company's growth trajectory is reflected in its revenue and earnings performance. The last actual revenue of 1.48 billion TWD and the last actual EPS of 6.72 TWD indicate a positive trend in the company's financial performance. The company's free cash flow of -35.31 million TWD suggests that it is not generating sufficient cash from its operations to cover its capital expenditures.
The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of net cash being negative after subtracting total debt suggests that the company may have some liquidity constraints. The company's operating cash flow of 161.78 million TWD is a positive indicator of its ability to generate cash from its operations.
Recent events and filings have not been specified in the provided data. However, the company's financial performance and risk assessment provide insights into its current state and potential future performance.
- 6569.TWO has a high price-to-earnings ratio of 33.62, indicating a premium valuation relative to its earnings.
- The company's return on equity of 7.14% and return on assets of 5.21% suggest moderate profitability.
- The company's liquidity is assessed as medium, with a current ratio of 2.17.
- The company's debt-to-equity ratio of 0.19 indicates a low level of financial leverage.
- The company's free cash flow is negative, indicating that it is not generating sufficient cash from its operations to cover its capital expenditures.
- margin_outlook_rationale: The company's gross profit margin is 33.05%, which is in line with industry norms, suggesting stable cost management.
- rd_outlook_rationale: The company's R&D investment is not specified, but the industry's focus on innovation implies ongoing R&D efforts.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 6569.TWO Market data — financials · 2026-05-27
- Onyx Healthcare Inc Market data — analyst estimates · 2026-05-27